Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 302 Pages
|HIV (人類免疫缺乏病毒):美國的醫藥品市場預測與分析 Human Immunodeficiency Virus (HIV) - US Drug Forecast and Market Analysis to 2023|
|出版日期: 2015年09月09日||內容資訊: 英文 302 Pages||
本報告提供美國的HIV (人類免疫缺乏病毒)治療藥臨床實驗趨勢與上市預測相關分析，提供您HIV概要 (病因·病理·症狀·診斷方法等) ，及目前的主要治療方法，現在臨床實驗中/已上市的開發中產品概要 (功效，SWOT分析及其它)，市場規模預測 (總計11年份)，主要推動市場要素等調查評估。
Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline's (GSK's) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.
Over the forecast period, the major driver of growth in the US HIV therapeutics market will be the launch of new drugs that offer improvements in terms of the pill burden, tolerability, and efficacy. Novel STRs will have the strongest positive impact on the market, and the drugs within this class of ART regimens include ViiV's recently launched INI-based STR, Triumeq, which was the first regimen to show superiority over Atripla.